1NCE
1NCE, a company offering a software platform for connected products, has won the award for “Best SaaS Innovation in the Internet of Things (IoT)” at the SaaS Awards.
The SaaS Awards recognize the leading innovations and applications of software-as-a-service solutions across a wide range of use cases and sectors. The program also named 1NCE a finalist in the “Best SaaS Newcomer” category.
1NCE’s novel proposition – transforming connectivity into a component within software – radically simplifies the supply chain of connectivity for companies across nearly every industry. Since evolving into software in 2022, 1NCE has become a fast-growing global standard in IoT, delivering tools to transform data into actionable insights with minimal effort. 1NCE customers can accelerate time-to-market for IoT projects by months, determine device location without GPS, and optimize transmission to increase battery life by up to 70 percent.
Rakesh Datta, Lead Judge said: “The SaaS Awards team thought it incredible to see how 1NCE has designed an IoT connectivity solution that caters to the two critical aspects of minimal power consumption as well as bandwidth usage. Their fixed-cost model combined with ease of global scalability are a mix rarely seen in the IoT space. Great customer feedback, great product in the IoT connectivity space. Congratulations 1NCE!”
New customers can get started today at the 1NCE online shop. Support is available in 25 languages.
About 1NCE
1NCE is a company offering a software platform for connected products that delivers future-proof, hassle-free IoT in 173 countries and regions. The software platform enables customers to easily, securely and reliably collect device data and turn it into actionable intelligence. This accelerates time-to-market for data collection projects by months, increases device lifetime by years, and allows efficient management of sensors from initial deployment to the end of the product lifecycle. More than 20,000 customers -- including 60 Fortune 500 companies -- trust 1NCE with 22 million connected products. Learn more at www.1NCE.com and follow on Facebook, LinkedIn and Twitter/X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822153793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Konfer Launches DORA Compliance Controls Catalog to Help EU Meet January 2025 Compliance Deadline, Partners With Leading Law Firm Osborne Clarke to Offer DORA Compliance Check to EU Organizations10.9.2024 10:00:00 CEST | Press release
Konfer, the Silicon Valley-based Agentic AI product company, today announced the launch of the Konfer DORA Compliance Controls Catalog to help EU financial institutions meet the January 2025 conformance deadline. The Konfer DORA Control Questions Catalog is designed to guide financial institutions through the complexities of the Digital Operational Resilience Act (DORA). Konfer’s AI agent has interpreted DORA’s extensive regulation, converting the obligations into practical control questions. These questions not only assess compliance but also integrate team responses to provide a detailed view of an organization's operational resilience, identifying potential vulnerabilities, and enhancing risk management processes. “The Konfer DORA Controls Catalog was designed to help EU financial institutions not just get a translation of the DORA compliance, but to actively implement the controls across their teams and operationalize compliance,” said Debu Chatterjee, CEO of Konfer. “It takes out
CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients10.9.2024 10:00:00 CEST | Press release
The Series B funding enables both an International Pivotal trial to diagnose MVO and a randomized controlled trial to evaluate therapeutic treatments for MVO through the CoFI system CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital, CorFlow's initial VC investor and largest shareholder. Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital participated in the multinational syndicate. Concurrent with the financing, David Prim of Broadview Ventures, Barbara Castellano of Panakes Partners, Yoann Bonnamour of Merieux Equity Partners, and Rhiya Pau of Laerdal Million Lives Fund have joined the CorFlow Board of Directors. The Series B will fund the MOCA II (MVO with CoFITM System Assessment II) pivotal study intended to gain US market clearance. The
Technology Reply Wins the 2024 Oracle Partner Awards - Europe South Innovation10.9.2024 09:30:00 CEST | Press release
Oracle recognizes Technology Reply’s ability to develop and deliver pioneering solutions through partnering with Oracle Oracle today announced that Technology Reply is a winner in the 2024 Oracle Partner Awards – Cloud/Technology Europe South Innovation. This award highlights partners that produced thought-leadership-level solutions that empower Oracle customers to meet their business goals and challenges through the partner’s innovative solution. Partners considered for this award have developed solutions that integrate multiple Oracle technologies and products and/or have integrated a third-party Oracle technology partner into their solution. Technology Reply, specialized in leveraging advanced AI and machine learning technologies, is dedicated to delivering innovative solutions that drive business transformation. The award-winning project was developed for Bitron, a global company that guides businesses in the development and production of electronic and mechatronic components, and
Sofinnova Partners appoints Karl Naegler as Partner10.9.2024 09:00:00 CEST | Press release
Seasoned investor with 20 years of experience and a strong track record strengthens VC’s leadership in early-stage life science investments Sofinnova Partners (“Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of Karl Naegler as Partner. This strategic hire also marks Sofinnova’s expansion into Germany, bolstering its reach and influence across Europe. Naegler will play a key role in Sofinnova Capital, the firm’s early-stage investment strategy, established 35 years ago. His expertise strengthens the firm’s commitment to championing early-stage innovation in life sciences and enhances a well-established team of partners. Before joining Sofinnova, Naegler was a Managing Partner at Wellington Partners Life Sciences and a Partner at Gimv, where he was instrumental in the success of several high-profile startups, from company formation to successful exit. These include Seamless Therapeutics, recently launche
MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors10.9.2024 09:00:00 CEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to the newly created role of Chief Business Officer. Concurrently, the company has strengthened its Board of Directors with the appointment of industry veteran Ron Robison, M.D. “We are excited to have Grégoire join our executive team at this pivotal moment for MRM Health, on the cusp of late-stage clinical development for our lead candidate MH002 in ulcerative colitis and pouchitis, from our proprietary CORAL platform designed to harness the full power of the gut microbiome to develop effective and safe therapeutics,” said Sam Possemiers, Ph.D., Chief Executive Officer of MRM Health. “Grégoire’s extensive expertise in corporate development, combined with his strategic acumen, will be crucial as we continue to advance our pipeline and expand our reach.” Mr. Franoux will lead the company’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom